The Department of Health — Abu Dhabi (DoH), has successfully completed a groundbreaking clinical trial in Abu Dhabi, in collaboration with Cellcolabs and Burjeel Holdings.
Developed by Swedish biotech company Cellcolabs, StromaForte has shown a favourable safety profile and significant therapeutic potential for knee osteoarthritis, marking a significant step in evaluating cell-based therapies for degenerative joint diseases.
